Athira Pharma, Inc.

NasdaqGS:ATHA Stock Report

Market Cap: US$21.0m

Athira Pharma Management

Management criteria checks 2/4

Athira Pharma's CEO is Mark Litton, appointed in Oct 2021, has a tenure of 3.17 years. total yearly compensation is $2.26M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth $97.05K. The average tenure of the management team and the board of directors is 1.9 years and 3 years respectively.

Key information

Mark Litton

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage25.9%
CEO tenure3.2yrs
CEO ownership0.5%
Management average tenure1.9yrs
Board average tenure3yrs

Recent management updates

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

CEO Compensation Analysis

How has Mark Litton's remuneration changed compared to Athira Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$109m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$116m

Dec 31 2023US$2mUS$585k

-US$118m

Sep 30 2023n/an/a

-US$121m

Jun 30 2023n/an/a

-US$108m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$4mUS$543k

-US$96m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$3mUS$450k

-US$55m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020n/an/a

-US$20m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$204kUS$12k

-US$5m

Compensation vs Market: Mark's total compensation ($USD2.26M) is above average for companies of similar size in the US market ($USD651.40K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Litton (56 yo)

3.2yrs

Tenure

US$2,261,564

Compensation

Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of Athira Pharma, Inc. since July 2019 until October 18, 2021 and serve...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Litton
President3.2yrsUS$2.26m0.46%
$ 97.0k
Robert Renninger
VP of Financeless than a yearno data0.20%
$ 41.5k
Kevin Church
Chief Scientific Officer1.9yrsUS$135.32k0.24%
$ 50.2k
Julie Rathbun
Head of Investor Relationsno datano datano data
Mark Worthington
General Counsel3.5yrsUS$2.71m0.13%
$ 28.1k
Javier San Martin
Chief Medical Officerless than a yearno datano data

1.9yrs

Average Tenure

56yo

Average Age

Experienced Management: ATHA's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Mark Litton
President3.2yrsUS$2.26m0.46%
$ 97.0k
John Fluke
Independent Director10yrsUS$95.89k0.37%
$ 78.5k
Grant Pickering
Independent Director2.9yrsUS$96.53k0.067%
$ 14.0k
Kelly Romano
Independent Chairwoman of the Board4yrsUS$124.68k0.21%
$ 43.7k
Joseph Edelman
Independent Director4.6yrsUS$92.77k0%
$ 0
Hans Moebius
Member of Scientific Advisory Board2.5yrsUS$1.29m0.24%
$ 49.6k
Marwan Sabbagh
Member of Scientific Advisory Board2.5yrsno datano data
Barbara Kosacz
Independent Director3.8yrsUS$102.39k0%
$ 0
Michael A. Panzara
Independent Director2.8yrsUS$89.36k0%
$ 0
James Johnson
Independent Director4.3yrsUS$106.87k0.013%
$ 2.7k
John Olichney
Member of Scientific Advisory Board2.5yrsno datano data
Anton Porsteinsson
Member of Scientific Advisory Board2.5yrsno datano data

3.0yrs

Average Tenure

64yo

Average Age

Experienced Board: ATHA's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 08:36
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Athira Pharma, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Thomas ShraderBTIG
Corinne JohnsonGoldman Sachs